NanoString Technologies, Inc. Stock

Equities

NSTGQ

US63009R1095

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets Other stock markets 03:56:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.1 ^USD	-8.00%		-.--%	-86.64%

May. 22	First Amended Disclosure Statement Approved for NanoString Technologies, Inc.	CI
May. 07	Bruker's NanoString Secures Patent Case Win in Germany	MT

Financials (USD)

Sales 2021	145M	Sales 2022	127M	Capitalization	372M
Net income 2021	-115M	Net income 2022	-160M	EV / Sales 2021	12.6 x
Net cash position 2021	96.5M	Net Debt 2022	54.3M	EV / Sales 2022	3.35 x
P/E ratio 2021	-16.6 x	P/E ratio 2022	-2.32 x	Employees	550
Yield 2021 *	-	Yield 2022	-	Free-Float	93.27%

More Fundamentals * Assessed data

Chart NanoString Technologies, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about NanoString Technologies, Inc.

First Amended Disclosure Statement Approved for NanoString Technologies, Inc.	May. 22	CI
Bruker's NanoString Secures Patent Case Win in Germany	May. 07	MT
First Amended Reorganization Plan and Disclosure Statement Filed by NanoString Technologies, Inc.	May. 07	CI
NanoString Technologies, Inc. Announces Termination of R. Bradley Gray as CEO	May. 06	CI
NanoString Technologies, Inc. Announces Termination of K. Thomas Bailey as Chief Financial Officer	May. 06	CI
NanoString Technologies, Inc. Announces Executive Changes	May. 06	CI
Bruker Corporation completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.	May. 05	CI
Bruker Agrees Signs Asset Purchase Deal With NanoString Technologies	Apr. 22	MT
Motion for Asset Sale Approved for NanoString Technologies, Inc.	Apr. 19	CI
Notice of Successful Bidder Filed by NanoString Technologies, Inc.	Apr. 17	CI
Bruker Corporation entered into an agreement to acquire Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q) for approximately $390 million.	Apr. 16	CI
North American Morning Briefing : Powell Comments, -2-	Apr. 16	DJ
Joint Reorganization Plan and Disclosure Statement Filed by NanoString Technologies, Inc.	Apr. 15	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ

More news

Latest transcript on NanoString Technologies, Inc.

NanoString Technologies, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM

Jan. 10

More transcripts

Analyst Recommendations on NanoString Technologies, Inc.

Canaccord Genuity Downgrades NanoString Technologies to Hold From Buy, Adjusts Price Target to $0.25 From $1.50	Feb. 12	MT
Canaccord Genuity Adjusts Price Target on NanoString Technologies to $1.50 From $5, Maintains Buy Rating	Nov. 27	MT
JPMorgan Downgrades NanoString Technologies to Neutral From Overweight	Nov. 27	MT
Baird Downgrades NanoString Technologies to Neutral From Outperform, Cuts Price Target to $0.75 From $4	Nov. 21	MT
TD Cowen Downgrades NanoString Technologies to Market Perform From Outperform, Cuts Price Target to $1.40 From $6	Nov. 20	MT

More recommendations

Press releases NanoString Technologies, Inc.

NanoString Technologies : Modification to Rights of Security Holders - Form 8-K	May. 28	PU
The UPC Court Of Appeal's First Decision: What Does It Mean For The Assessment Of Inventive Step At The UPC?	Apr. 16	AQ
NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research Conference	Apr. 05	AQ
UPC CoA: No Stay Of UPC Court Proceedings During Chapter 11 Proceedings	Mar. 15	AQ
NanoString Announces Completion of Financing to Support Restructuring Process	Feb. 12	AQ

More press releases

News in other languages on NanoString Technologies, Inc.

NanoString nimmt Stellung zur Entscheidung des Landgerichts München	23-05-18
Starbucks se vincula con Amazon Go para servir cafés sin cajero	21-11-18
NanoString Technologies : Prosigna, der Brustkrebstest von NanoString Technologies, wurde in die deutsche Leitlinie zur Behandlung von Brustkrebs aufgenommen	15-03-18
NanoString Technologies Inc : Eine in The Journal of Clinical Oncology veröffentlichte Studie weist Vorteile von NanoStrings Prosigna? Brustkrebsanalyse nach	13-07-02
NanoString Technologies Inc : Eine in The Journal of Clinical Oncology veröffentlichte Studie weist Vorteile von NanoStrings Prosigna? Brustkrebsanalyse nach	13-07-02

More news

Quotes and Performance

1 day	-8.00%
1 month	-47.37%
3 months	+11.11%
6 months	-81.96%
Current year	-86.64%

More quotes

Highs and lows

1 week

0.09

0.12

1 month

0.07

0.21

Current year

0.04

0.84

1 year

0.04

6.29

3 years

0.04

70.40

5 years

0.04

86.42

10 years

0.04

86.42

More quotes

Managers and Directors - NanoString Technologies, Inc.

Managers	Title	Age	Since
Mark A. Winham COO	Chief Operating Officer	-	19-10-01
Douglas Farrell IRC	Investor Relations Contact	-	-
Todd Garland PRN	Corporate Officer/Principal	55	23-08-27

Members of the board	Title	Age	Since
Kirk Malloy BRD	Director/Board Member	57	16-09-11
William Young CHM	Chairman	79	10-02-28
Chad Waite BRD	Director/Board Member	69	04-06-30

More insiders

ETFs positioned on NanoString Technologies, Inc.

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.06%	0 M€	0.00%	-
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.04%	0 M€	0.00%	-
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	0.02%	2 M€	-.--%

More ETFs positioned on NanoString Technologies, Inc.

Quotes

Date	Price	Change	Volume
24-05-31	0.1	-8.00%	365,446
24-05-30	0.1087	-9.34%	318,234
24-05-29	0.1199	+30.04%	876,250
24-05-28	0.0922	-7.80%	383,431
24-05-24	0.1	+8.58%	336,785

Delayed Quote OTC Markets, May 31, 2024 at 03:56 pm EDT

More quotes

Company Profile

NS Wind Down Co., Inc., formerly NanoString Technologies, Inc., has filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code. The Company has no business operations.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NANOSTRING TECHNOLOGIES, INC.	-86.64%	4.81M
ABBOTT LABORATORIES	-7.16%	178B
MEDTRONIC PLC	-1.23%	107B
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B
DEXCOM, INC.	-4.28%	47.23B
CENCORA, INC.	+10.32%	44.62B
HOYA CORPORATION	+8.14%	42.5B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.76%	29.99B
TERUMO CORPORATION	+15.53%	25.22B
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B

Other Medical Equipment, Supplies & Distribution